open access

Vol 10, No 6 (2014)
Review paper
Published online: 2015-01-07
Get Citation

Discussion on the use of bevacizumab as first line palliative therapy in patients with colorectal cancer with metastases limited to the liver

Krzysztof Adamowicz, Marzena Wełnicka-Jaśkiewicz
Onkol. Prak. Klin 2014;10(6):330-335.

open access

Vol 10, No 6 (2014)
REVIEW ARTICLES
Published online: 2015-01-07

Abstract

Colorectal cancer (CRC) is the third most commonly diagnosed cancer in the world (excluding non-melanoma skin cancers). Worldwide, CRC is responsible for over 600,000 deaths annually and remains a significant public health concern. Because of therapeutic advancements over the past two decades, patients with metastatic CRC are living longer with an improved quality of life. Cytotoxic treatment regimens have demonstrated greater efficacy and contributed to a significant improvement in survival. Strategies for treating CRC are varied, but often use chemotherapy in combination with targeted therapies (biological). Bevacizumab is a recombinant humanized monoclonal antibody that selectively binds to human vascular endothelial growth factor. It is crucial that all treatment decisions for systemic colorectal liver metastases should derived based on appropriate multidisciplinary considerations.

Abstract

Colorectal cancer (CRC) is the third most commonly diagnosed cancer in the world (excluding non-melanoma skin cancers). Worldwide, CRC is responsible for over 600,000 deaths annually and remains a significant public health concern. Because of therapeutic advancements over the past two decades, patients with metastatic CRC are living longer with an improved quality of life. Cytotoxic treatment regimens have demonstrated greater efficacy and contributed to a significant improvement in survival. Strategies for treating CRC are varied, but often use chemotherapy in combination with targeted therapies (biological). Bevacizumab is a recombinant humanized monoclonal antibody that selectively binds to human vascular endothelial growth factor. It is crucial that all treatment decisions for systemic colorectal liver metastases should derived based on appropriate multidisciplinary considerations.

Get Citation

Keywords

colorectal cancer, chemotherapy, bevacizumab

About this article
Title

Discussion on the use of bevacizumab as first line palliative therapy in patients with colorectal cancer with metastases limited to the liver

Journal

Oncology in Clinical Practice

Issue

Vol 10, No 6 (2014)

Article type

Review paper

Pages

330-335

Published online

2015-01-07

Bibliographic record

Onkol. Prak. Klin 2014;10(6):330-335.

Keywords

colorectal cancer
chemotherapy
bevacizumab

Authors

Krzysztof Adamowicz
Marzena Wełnicka-Jaśkiewicz

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl